On November 7, 2018 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, reported upcoming presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 33rd Annual Meeting and participation in an analyst-moderated Q&A panel at Cowen’s 2nd Annual IO NEXT Summit (Press release, Curis, NOV 7, 2018, View Source [SID1234530914]). Curis’ poster presentations will take place on Friday, Nov. 9, with a poster from collaborator Aurigene on Saturday, Nov. 10, at Hall E of the Walter E. Washington Convention Center in Washington, D.C. The Cowen 2nd Annual IO NEXT Summit will take place at the Marriott Marquis in Washington, D.C. featuring a discussion with Jim Dentzer, President and CEO, and Dr. Robert Martell, Head of Research and Development, in an analyst-hosted fireside chat.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In three posters at the SITC (Free SITC Whitepaper) conference, Curis will present evidence supporting the presence of high VISTA expression on tumor cells, preclinical data supporting VISTA’s ability to independently suppress T cell responses, and Phase 1 clinical trial data of CA-170 in patients with advanced tumors and lymphomas. In addition, Curis collaborator Aurigene will present a poster detailing key findings from its ongoing Phase 2 trial of CA-170 in patients with advanced solid tumors and Hodgkin lymphoma who are immunotherapy treatment-naïve.
Details of these presentations are as follows:
Cowen IO NEXT Summit
Date/Time:
Friday, Nov. 09, 11:50 AM – 12:10 PM EST
Presenters:
Jim Dentzer, President and Chief Executive Officer
Robert Martell, M.D., Ph.D., Head of Research and Development
Location:
Marriot Marquis Washington, DC
Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 33rd Annual Meeting
CA-170 Poster Presentations from Curis:
Date/Time:
Friday, Nov. 9, 12:45 PM – 2:15 PM, 6:30 PM – 8:00 PM EST
Location:
Hall E, Walter E. Washington Convention Center
Abstract Number:
P135
Presentation Title:
Integrative genomic and proteomic analysis identifies cancer subtypes and signaling networks associated with aberrant tumor expression of VISTA
Abstract Number:
P139
Presentation Title:
Pharmacodynamic effects of CA-170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of T-cell activation (VISTA) and PDL1
Abstract Number:
P341
Presentation Title:
Phase 1 study of CA-170, a first-in-class, orally available, small molecule immune checkpoint inhibitor (ICI) dually targeting VISTA and PDL1, in patients with advanced solid tumors or lymphomas
CA-170 Poster Presentation from Aurigene:
Date/Time:
Saturday, Nov. 10, 12:20 PM – 1:50 PM, 7:00 PM – 8:30 PM EST
Location:
Hall E, Walter E. Washington Convention Center
Abstract Number:
P714
Presentation Title:
Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients with advanced solid tumor and Hodgkin lymphoma